Abnormal uterine bleeding

Two regimens of medroxyprogesterone acetate for treatment of endometrial hyperplasia without atypia : a randomized clinical trial

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

PACTR

Registry ID

PACTR201508001237608

Enrollment

100

Registered

2015-08-12

Start date

2015-09-01

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Fertility-female treatment of endometrial hyperplasia without atypia

Interventions

Group 1(Cyclic MPA group)

continuous MPA group

Eligibility

Sex/Gender

Female

Inclusion criteria

Inclusion criteria: no prior diagnosis of endometrial carcinoma, an intact uterus, with histologically confirmed endometrial hyperplasia (EH) without atypia

Exclusion criteria

Exclusion criteria: Women with associated pathology as uterine fibroid, cervical or vaginal pathology, bleeding tendency, chronic liver disease and any contraindications to progestin therapy were excluded from the study.

Design outcomes

Primary

Measure	Time frame
regression of hyperplasia after 6 months of progestin therapy.	—

Secondary

Measure	Time frame
adverse effects;patient acceptability	—

Countries

Egypt

Contacts

Public ContactRagab Dawood

Lecturer of Obstetrics and Gynecology-Faculty of Medicine-Menoufia University

dr_ragabdawood@yahoo.com002010146256413

Outcome results

None listed

Source: PACTR (via WHO ICTRP) · Data processed: Aug 9, 2026